A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Recruiting
Observational Study
Cytomegalovirus (CMV)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 75 (estimated)
- Sponsor
- Takeda · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.
The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participant signed an informed consent form.
* Aged greater than or equal to (\>=) 18 years at the time of consent.
* Received an HSCT/SOT.
* Diagnosed with CMV infection/disease any time after the HSCT/SOT date.
* Starting maribavir for the first time and in line with the Bel…
Contacts